Abbott Makes Good On IDev Buy With Supera Peripheral Stent Approval
This article was originally published in The Gray Sheet
Executive Summary
Abbott announced PMA-approval of the Supera stent, which it gained in a $310 million acquisition of IDev Technologies last year. The approval gives Abbott a device specific for the superficial femoral artery, which the company says is one of the largest and fastest growing segments of the peripheral stent market.
You may also be interested in...
FDA Approval Listing: Three Original PMAs In March
FDA posted its official listing of March PMAs this week, including original PMA approvals for devices from Abbott Laboratories, Cochlear Ltd. and Roche Diagnostics. Also, average time-to-decision data for PMA supplements.
Abbott Ups Vascular, Ophthalmic Focus With Two Acquisitions
Abbott Laboratories announced July 15 it has entered into agreements to purchase stent manufacturer IDev Technologies and ophthalmic device company OptiMedica Corp. The acquisitions are intended to bolster the company’s medical device unit in the vascular and vision care businesses, respectively.
Bard’s LifeStent Gets Legs: PMA Approved For Femoral, Popliteal Arteries
C.R. Bard is now able to market its LifeStent for treating occluded leg arteries with a PMA approval announced Feb. 17